article thumbnail

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. There are currently over 700 immuno-oncology products in Phase I-III of development in the eight major markets, said Chalk.

Marketing 264
article thumbnail

Why DTC isn’t, and is, marketing

World of DTC Marketing

CPG marketers are trying to maintain market share amid price increases and smaller product sizes, leading to a more significant jump in consumerism. But, in pharma marketing, the changes affect every product category. However, DTC marketing is different, much different. So what’s the opportunity for DTC marketers?

Marketing 252
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Current and future players in the lupus market

Pharmaceutical Technology

As such, the SLE and LN marketplace is dominated by generics, and GSK’s Benlysta and AstraZeneca’s Saphnelo are the only drugs that have gained marketing approval specifically for SLE in more than 50 years. In previous years, Benlysta has managed to grow the lupus market in terms of value, having generated approximately $492.9m

Marketing 278
article thumbnail

EC grants marketing authorisation for Sandoz’s biosimilar Hyrimoz

Pharmaceutical Technology

The European Commission (EC) has granted marketing authorisation for Sandoz’s biosimilar Hyrimoz (adalimumab) citrate-free high-concentration formulation (HCF). With eight marketed biosimilars, Sandoz is offering the broadest biosimilar portfolio and is the leading biosimilars company in Europe, with more than two decades of experience.

Marketing 264
article thumbnail

Takeda discontinuing in AAV and rare haematology disease markets

Pharmaceutical Technology

With challenges around the R&D, clinical trials, pricing, and market access for these rare disease therapeutics, big pharma often collaborates with specialist biotechnology companies as a method of de-risking the development of gene therapy products.

article thumbnail

EMA validates Sobi’s marketing authorisation application for efanesoctocog alfa

Pharmaceutical Technology

The European Medicines Agency (EMA) has accepted and verified Sobi’s marketing authorisation application for a new factor VIII (FVIII), efanesoctocog alfa, to treat haemophilia A patients of all ages.

Marketing 217
article thumbnail

The Mexico pharma market: growth factors and advantages for manufacturing

Pharmaceutical Technology

Mexico is Latin America’s second-largest pharmaceutical market and ranks in the top 15 on the global list of biggest pharma markets. Furthermore, the Mexican market typically favors branded products over generics, making the country a highly suitable location to license innovative medicines. million has coverage.